Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 383 entries
Sorted by: Best Match Show Resources per page
Methotrexate: optimizing the efficacy in rheumatoid arthritis.

Therapeutic advances in musculoskeletal disease

Braun J.
PMID: 22870474
Ther Adv Musculoskelet Dis. 2011 Jun;3(3):151-8. doi: 10.1177/1759720X11408635.

Methotrexate (MTX) is currently the most frequently used drugs in the treatment of rheumatoid arthritis (RA). The drug had been synthesized in 1948 and first tests to treat patients with psoriasis and RA were published in 1951. However, until...

Cite
Braun J. Methotrexate: optimizing the efficacy in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2011;3(3):151-8doi: 10.1177/1759720X11408635.
Braun, J. (2011). Methotrexate: optimizing the efficacy in rheumatoid arthritis. Therapeutic advances in musculoskeletal disease, 3(3), 151-8. https://doi.org/10.1177/1759720X11408635
Braun, Jürgen. "Methotrexate: optimizing the efficacy in rheumatoid arthritis." Therapeutic advances in musculoskeletal disease vol. 3,3 (2011): 151-8. doi: https://doi.org/10.1177/1759720X11408635
Braun J. Methotrexate: optimizing the efficacy in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2011 Jun;3(3):151-8. doi: 10.1177/1759720X11408635. PMID: 22870474; PMCID: PMC3389391.
Copy Download .nbib Format: NLM
Cilostazol against 2,4,6-trinitrobenzene sulfonic acid-induced colitis: Effect on tight junction, inflammation, and apoptosis.

JGH open : an open access journal of gastroenterology and hepatology

Al-Kishali HA, Abd El Fattah MA, Mohammad WA, El-Abhar HS.
PMID: 31406920
JGH Open. 2019 Mar 29;3(4):281-289. doi: 10.1002/jgh3.12148. eCollection 2019 Aug.

BACKGROUND: Inflammatory bowel diseases are immunologically mediated disorders of gastrointestinal tract, characterized by dysregulated immune responses that result in a chronic intestinal inflammation. The antiplatelet cilostazol (CS), a phosphodiesterase-III inhibitor, exerted a beneficial effect on several models of gastrointestinal...

Cite
Al-Kishali HA, Abd El Fattah MA, Mohammad WA, et al. Cilostazol against 2,4,6-trinitrobenzene sulfonic acid-induced colitis: Effect on tight junction, inflammation, and apoptosis. JGH Open. 2019;3(4):281-289doi: 10.1002/jgh3.12148.
Al-Kishali, H. A., Abd El Fattah, M. A., Mohammad, W. A., & El-Abhar, H. S. (2019). Cilostazol against 2,4,6-trinitrobenzene sulfonic acid-induced colitis: Effect on tight junction, inflammation, and apoptosis. JGH open : an open access journal of gastroenterology and hepatology, 3(4), 281-289. https://doi.org/10.1002/jgh3.12148
Al-Kishali, Hiba A, et al. "Cilostazol against 2,4,6-trinitrobenzene sulfonic acid-induced colitis: Effect on tight junction, inflammation, and apoptosis." JGH open : an open access journal of gastroenterology and hepatology vol. 3,4 (2019): 281-289. doi: https://doi.org/10.1002/jgh3.12148
Al-Kishali HA, Abd El Fattah MA, Mohammad WA, El-Abhar HS. Cilostazol against 2,4,6-trinitrobenzene sulfonic acid-induced colitis: Effect on tight junction, inflammation, and apoptosis. JGH Open. 2019 Mar 29;3(4):281-289. doi: 10.1002/jgh3.12148. eCollection 2019 Aug. PMID: 31406920; PMCID: PMC6684512.
Copy Download .nbib Format: NLM
Protective effects of conventional and colon-targeted lycopene and linalool on ulcerative colitis induced by acetic acid in rats.

Inflammopharmacology

Tekeli İO, Ateşşahin A, Sakin F, Aslan A, Çeribaşı S, Yipel M.
PMID: 29736689
Inflammopharmacology. 2018 May 07; doi: 10.1007/s10787-018-0485-x. Epub 2018 May 07.

OBJECTIVE: To compare the potential protective effects of conventional and colon-targeted lycopene (TLC) and linalool (TLN) on acetic acid (AA)-induced ulcerative colitis (UC) in rats.METHODS: Conventional and colon-targeted LC (10 mg/kg) and LN (200 mg/kg) were administered in vivo...

Cite
Tekeli İO, Ateşşahin A, Sakin F, et al. Protective effects of conventional and colon-targeted lycopene and linalool on ulcerative colitis induced by acetic acid in rats. Inflammopharmacology. 2018;doi: 10.1007/s10787-018-0485-x.
Tekeli, �. �. O., Ateşşahin, A., Sakin, F., Aslan, A., Çeribaşı, S., & Yipel, M. (2018). Protective effects of conventional and colon-targeted lycopene and linalool on ulcerative colitis induced by acetic acid in rats. Inflammopharmacology, . https://doi.org/10.1007/s10787-018-0485-x
Tekeli, İbrahim Ozan, et al. "Protective effects of conventional and colon-targeted lycopene and linalool on ulcerative colitis induced by acetic acid in rats." Inflammopharmacology vol. (2018). doi: https://doi.org/10.1007/s10787-018-0485-x
Tekeli İO, Ateşşahin A, Sakin F, Aslan A, Çeribaşı S, Yipel M. Protective effects of conventional and colon-targeted lycopene and linalool on ulcerative colitis induced by acetic acid in rats. Inflammopharmacology. 2018 May 07; doi: 10.1007/s10787-018-0485-x. Epub 2018 May 07. PMID: 29736689.
Copy Download .nbib Format: NLM
Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis.

Experimental and therapeutic medicine

Liu YF, Dong H, Tu SH, Zheng CH, Liu PL, Hu YH.
PMID: 25289064
Exp Ther Med. 2014 Nov;8(5):1585-1592. doi: 10.3892/etm.2014.1974. Epub 2014 Sep 17.

Etanercept (ETN) has been widely applied in the treatment of ankylosing spondylitis (AS). As the use of ETN has increased, associated adverse effects have been reported frequently. Previous meta-analyses have focused on comparing the differences in clinical outcomes between...

Cite
Liu YF, Dong H, Tu SH, et al. Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis. Exp Ther Med. 2014;8(5):1585-1592doi: 10.3892/etm.2014.1974.
Liu, Y. F., Dong, H., Tu, S. H., Zheng, C. H., Liu, P. L., & Hu, Y. H. (2014). Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis. Experimental and therapeutic medicine, 8(5), 1585-1592. https://doi.org/10.3892/etm.2014.1974
Liu, Ya-Fei, et al. "Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis." Experimental and therapeutic medicine vol. 8,5 (2014): 1585-1592. doi: https://doi.org/10.3892/etm.2014.1974
Liu YF, Dong H, Tu SH, Zheng CH, Liu PL, Hu YH. Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis. Exp Ther Med. 2014 Nov;8(5):1585-1592. doi: 10.3892/etm.2014.1974. Epub 2014 Sep 17. PMID: 25289064; PMCID: PMC4186333.
Copy Download .nbib Format: NLM
Probiotic Medilac-S.

World journal of clinical cases

Sohail G, Xu X, Christman MC, Tompkins TA.
PMID: 30568952
World J Clin Cases. 2018 Dec 06;6(15):961-984. doi: 10.12998/wjcc.v6.i15.961.

AIM: To assess the effects of probiotic Medilac-SMETHODS: A systematic literature search was conducted to find randomized, controlled trials in a Chinese population with at least two study arms - a control arm which receives a conventional, oral aminosalicylate...

Cite
Sohail G, Xu X, Christman MC, et al. Probiotic Medilac-S. World J Clin Cases. 2018;6(15):961-984doi: 10.12998/wjcc.v6.i15.961.
Sohail, G., Xu, X., Christman, M. C., & Tompkins, T. A. (2018). Probiotic Medilac-S. World journal of clinical cases, 6(15), 961-984. https://doi.org/10.12998/wjcc.v6.i15.961
Sohail, Ghania, et al. "Probiotic Medilac-S." World journal of clinical cases vol. 6,15 (2018): 961-984. doi: https://doi.org/10.12998/wjcc.v6.i15.961
Sohail G, Xu X, Christman MC, Tompkins TA. Probiotic Medilac-S. World J Clin Cases. 2018 Dec 06;6(15):961-984. doi: 10.12998/wjcc.v6.i15.961. PMID: 30568952; PMCID: PMC6288505.
Copy Download .nbib Format: NLM
Sulfasalazine-induced renal and hepatic injury in rats and the protective role of taurine.

BioImpacts : BI

Heidari R, Rasti M, Shirazi Yeganeh B, Niknahad H, Saeedi A, Najibi A.
PMID: 27340618
Bioimpacts. 2016;6(1):3-8. doi: 10.15171/bi.2016.01. Epub 2016 Mar 28.

INTRODUCTION: Sulfasalazine is a drug commonly administrated against inflammatory-based disorders. On the other hand, kidney and liver injury are serious adverse events accompanied by sulfasalazine administration. No specific therapeutic option is available against this complication. The current investigation was...

Cite
Heidari R, Rasti M, Shirazi Yeganeh B, et al. Sulfasalazine-induced renal and hepatic injury in rats and the protective role of taurine. Bioimpacts. 2016;6(1):3-8doi: 10.15171/bi.2016.01.
Heidari, R., Rasti, M., Shirazi Yeganeh, B., Niknahad, H., Saeedi, A., & Najibi, A. (2016). Sulfasalazine-induced renal and hepatic injury in rats and the protective role of taurine. BioImpacts : BI, 6(1), 3-8. https://doi.org/10.15171/bi.2016.01
Heidari, Reza, et al. "Sulfasalazine-induced renal and hepatic injury in rats and the protective role of taurine." BioImpacts : BI vol. 6,1 (2016): 3-8. doi: https://doi.org/10.15171/bi.2016.01
Heidari R, Rasti M, Shirazi Yeganeh B, Niknahad H, Saeedi A, Najibi A. Sulfasalazine-induced renal and hepatic injury in rats and the protective role of taurine. Bioimpacts. 2016;6(1):3-8. doi: 10.15171/bi.2016.01. Epub 2016 Mar 28. PMID: 27340618; PMCID: PMC4916549.
Copy Download .nbib Format: NLM
Gut microbiota-driven drug metabolism in inflammatory bowel disease.

Journal of Crohn's & colitis

Crouwel F, Buiter HJC, de Boer NK.
PMID: 32652007
J Crohns Colitis. 2020 Jul 11; doi: 10.1093/ecco-jcc/jjaa143. Epub 2020 Jul 11.

BACKGROUND AND AIMS: The gut microbiota plays an important role in the metabolization and modulation of several types of drugs. With this study we aimed to review the literature about microbial drug metabolism of medication prescribed in inflammatory bowel...

Cite
Crouwel F, Buiter HJC, de Boer NK. Gut microbiota-driven drug metabolism in inflammatory bowel disease. J Crohns Colitis. 2020;doi: 10.1093/ecco-jcc/jjaa143.
Crouwel, F., Buiter, H. J. C., & de Boer, N. K. (2020). Gut microbiota-driven drug metabolism in inflammatory bowel disease. Journal of Crohn's & colitis, . https://doi.org/10.1093/ecco-jcc/jjaa143
Crouwel, Femke, et al. "Gut microbiota-driven drug metabolism in inflammatory bowel disease." Journal of Crohn's & colitis vol. (2020). doi: https://doi.org/10.1093/ecco-jcc/jjaa143
Crouwel F, Buiter HJC, de Boer NK. Gut microbiota-driven drug metabolism in inflammatory bowel disease. J Crohns Colitis. 2020 Jul 11; doi: 10.1093/ecco-jcc/jjaa143. Epub 2020 Jul 11. PMID: 32652007; PMCID: PMC7904070.
Copy Download .nbib Format: NLM
Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis: Republished.

Inflammatory bowel diseases

Coward S, Kuenzig ME, Hazlewood G, Clement F, McBrien K, Holmes R, Panaccione R, Ghosh S, Seow CH, Rezaie A, Kaplan GG.
PMID: 30052985
Inflamm Bowel Dis. 2017 May 01;23(5):E26-E37. doi: 10.1097/MIB.0000000000001158.

BACKGROUND: Induction treatment of mild-to-moderate Crohn's disease is controversial.PURPOSE: To compare the induction of remission between different doses of mesalamine, sulfasalazine, corticosteroids, and budesonide for active Crohn's disease.DATA SOURCES: We identified randomized controlled trials from existing Cochrane reviews and...

Cite
Coward S, Kuenzig ME, Hazlewood G, et al. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis: Republished. Inflamm Bowel Dis. 2017;23(5):E26-E37doi: 10.1097/MIB.0000000000001158.
Coward, S., Kuenzig, M. E., Hazlewood, G., Clement, F., McBrien, K., Holmes, R., Panaccione, R., Ghosh, S., Seow, C. H., Rezaie, A., & Kaplan, G. G. (2017). Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis: Republished. Inflammatory bowel diseases, 23(5), E26-E37. https://doi.org/10.1097/MIB.0000000000001158
Coward, Stephanie, et al. "Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis: Republished." Inflammatory bowel diseases vol. 23,5 (2017): E26-E37. doi: https://doi.org/10.1097/MIB.0000000000001158
Coward S, Kuenzig ME, Hazlewood G, Clement F, McBrien K, Holmes R, Panaccione R, Ghosh S, Seow CH, Rezaie A, Kaplan GG. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis: Republished. Inflamm Bowel Dis. 2017 May 01;23(5):E26-E37. doi: 10.1097/MIB.0000000000001158. PMID: 30052985.
Copy Download .nbib Format: NLM
Letter by Lu et al. regarding article, "Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia".

Hypertension in pregnancy

Deng Z, Lu D.
PMID: 34978249
Hypertens Pregnancy. 2022 Jan 02;1-2. doi: 10.1080/10641955.2021.2024224. Epub 2022 Jan 02.

No abstract available.

Cite
Deng Z, Lu D. Letter by Lu et al. regarding article, "Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia". Hypertens Pregnancy. 2022;1-2doi: 10.1080/10641955.2021.2024224.
Deng, Z., & Lu, D. (2022). Letter by Lu et al. regarding article, "Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia". Hypertension in pregnancy, 1-2. https://doi.org/10.1080/10641955.2021.2024224
Deng, Zhuo, and Lu, Dan. "Letter by Lu et al. regarding article, "Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia"." Hypertension in pregnancy vol. (2022): 1-2. doi: https://doi.org/10.1080/10641955.2021.2024224
Deng Z, Lu D. Letter by Lu et al. regarding article, "Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia". Hypertens Pregnancy. 2022 Jan 02;1-2. doi: 10.1080/10641955.2021.2024224. Epub 2022 Jan 02. PMID: 34978249.
Copy Download .nbib Format: NLM
Erratum: Sulfasalazine Inhibits Inflammation and Fibrogenesis in Pancreas via NF-κB Signaling Pathway in Rats with Oxidative Stress-Induced Pancreatic Injury [Corrigendum].

Drug design, development and therapy

[No authors listed]
PMID: 34163142
Drug Des Devel Ther. 2021 Jun 16;15:2563. doi: 10.2147/DDDT.S324356. eCollection 2021.

[This corrects the article DOI: 10.2147/DDDT.S107679.].

Cite
Erratum: Sulfasalazine Inhibits Inflammation and Fibrogenesis in Pancreas via NF-κB Signaling Pathway in Rats with Oxidative Stress-Induced Pancreatic Injury [Corrigendum]. Drug Des Devel Ther. 2021;15:2563doi: 10.2147/DDDT.S324356.
(2021). Erratum: Sulfasalazine Inhibits Inflammation and Fibrogenesis in Pancreas via NF-κB Signaling Pathway in Rats with Oxidative Stress-Induced Pancreatic Injury [Corrigendum]. Drug design, development and therapy, 152563. https://doi.org/10.2147/DDDT.S324356
"Erratum: Sulfasalazine Inhibits Inflammation and Fibrogenesis in Pancreas via NF-κB Signaling Pathway in Rats with Oxidative Stress-Induced Pancreatic Injury [Corrigendum]." Drug design, development and therapy vol. 15 (2021): 2563. doi: https://doi.org/10.2147/DDDT.S324356
Erratum: Sulfasalazine Inhibits Inflammation and Fibrogenesis in Pancreas via NF-κB Signaling Pathway in Rats with Oxidative Stress-Induced Pancreatic Injury [Corrigendum]. Drug Des Devel Ther. 2021 Jun 16;15:2563. doi: 10.2147/DDDT.S324356. eCollection 2021. PMID: 34163142; PMCID: PMC8215931.
Copy Download .nbib Format: NLM
Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis.

ACR open rheumatology

Pokharel G, Deardon R, Barnabe C, Bykerk V, Bartlett SJ, Bessette L, Boire G, Hitchon CA, Keystone E, Pope J, Schieir O, Tin D, Thorne C, Hazlewood GS.
PMID: 31777827
ACR Open Rheumatol. 2019 Aug 08;1(8):471-479. doi: 10.1002/acr2.11052. eCollection 2019 Oct.

OBJECTIVE: To jointly estimate American College of Rheumatology (ACR50) response (a more commonly reported outcome) and remission (a more clinically relevant outcome) for methotrexate (MTX)-based treatment options in rheumatoid arthritis (RA).METHODS: We conducted a bivariate network meta-analysis (NMA) to...

Cite
Pokharel G, Deardon R, Barnabe C, et al. Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis. ACR Open Rheumatol. 2019;1(8):471-479doi: 10.1002/acr2.11052.
Pokharel, G., Deardon, R., Barnabe, C., Bykerk, V., Bartlett, S. J., Bessette, L., Boire, G., Hitchon, C. A., Keystone, E., Pope, J., Schieir, O., Tin, D., Thorne, C., Hazlewood, G. S. (2019). Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis. ACR open rheumatology, 1(8), 471-479. https://doi.org/10.1002/acr2.11052
Pokharel, Gyanendra, et al. "Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis." ACR open rheumatology vol. 1,8 (2019): 471-479. doi: https://doi.org/10.1002/acr2.11052
Pokharel G, Deardon R, Barnabe C, Bykerk V, Bartlett SJ, Bessette L, Boire G, Hitchon CA, Keystone E, Pope J, Schieir O, Tin D, Thorne C, Hazlewood GS. Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis. ACR Open Rheumatol. 2019 Aug 08;1(8):471-479. doi: 10.1002/acr2.11052. eCollection 2019 Oct. PMID: 31777827; PMCID: PMC6858043.
Copy Download .nbib Format: NLM
Protective and Therapeutic Effects of Aloe Vera Gel on Ulcerative Colitis Induced by Acetic Acid in Rats.

Clinical nutrition research

Bahrami G, Malekshahi H, Miraghaee S, Madani H, Babaei A, Mohammadi B, Hatami R.
PMID: 32789152
Clin Nutr Res. 2020 Jul 30;9(3):223-234. doi: 10.7762/cnr.2020.9.3.223. eCollection 2020 Jul.

Ulcerative colitis (UC) is a chronic intestinal inflammation. Common clinical symptoms are weight loss, diarrhea, ulcers, and inflammation. Aloe vera (AV) has several medicinal properties including antioxidant, anti-inflammatory analgesic, and improvement of gastric and skin ulcers. This study aimed...

Cite
Bahrami G, Malekshahi H, Miraghaee S, et al. Protective and Therapeutic Effects of Aloe Vera Gel on Ulcerative Colitis Induced by Acetic Acid in Rats. Clin Nutr Res. 2020;9(3):223-234doi: 10.7762/cnr.2020.9.3.223.
Bahrami, G., Malekshahi, H., Miraghaee, S., Madani, H., Babaei, A., Mohammadi, B., & Hatami, R. (2020). Protective and Therapeutic Effects of Aloe Vera Gel on Ulcerative Colitis Induced by Acetic Acid in Rats. Clinical nutrition research, 9(3), 223-234. https://doi.org/10.7762/cnr.2020.9.3.223
Bahrami, Gholamreza, et al. "Protective and Therapeutic Effects of Aloe Vera Gel on Ulcerative Colitis Induced by Acetic Acid in Rats." Clinical nutrition research vol. 9,3 (2020): 223-234. doi: https://doi.org/10.7762/cnr.2020.9.3.223
Bahrami G, Malekshahi H, Miraghaee S, Madani H, Babaei A, Mohammadi B, Hatami R. Protective and Therapeutic Effects of Aloe Vera Gel on Ulcerative Colitis Induced by Acetic Acid in Rats. Clin Nutr Res. 2020 Jul 30;9(3):223-234. doi: 10.7762/cnr.2020.9.3.223. eCollection 2020 Jul. PMID: 32789152; PMCID: PMC7402976.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 383 entries